Literature DB >> 25465279

Reduction of prohibitin expression contributes to left ventricular hypertrophy via enhancement of mitochondrial reactive oxygen species formation in spontaneous hypertensive rats.

H Zheng1, G M Lu.   

Abstract

Left ventricular hypertrophy (LVH) in hypertension is characterized by thickening of myocardium and decrease in heart chamber volume in response to mechanical or pathological stress, but the underlying molecular mechanisms remain to be defined. In this work, we investigate whether mitochondrial prohibitin (PHB) was involved in the progression of LVH in spontaneous hypertensive rats (SHR). First, it was found that mitochondrial dysfunction occurred in left ventricles of SHR. Through analysis using quantitative reverse transcription polymerase chain reaction and Western blotting, it was found that PHB mRNA and mitochondrial PHB levels in left ventricles of SHR were significantly lower than that in Wistar-Kyoto rats. Furthermore, PHB mRNA levels were negatively correlated to left ventricles weight-to-body weight ratio in SHR. Knockdown of PHB led to increased formation of mitochondrial reactive oxygen species (ROS) and reduced activities of complex I, mitochondrial adenosine triphosphate generation and mitochondrial membrane potential in cultured cardiomyocytes. Knockdown of PHB contributed to the cardiomyocyte hypertrophy, which could be attenuated by treatment with the Tempol. Angiotensin II (AngII) was increased in plasma and left ventricles of SHR. Incubation with AngII reduced mitochondrial PHB expression in cardiomyocytes, which was reversed when pretreated with losartan. In conclusion, reduction of PHB expression in left ventricles in SHR contributed to LVH, at least in part, through promoting mitochondrial ROS formation.

Entities:  

Keywords:  angiotensin II; left ventricular hypertrophy; mitochondria; prohibitin; reactive oxygen species; spontaneously hypertensive rats

Mesh:

Substances:

Year:  2014        PMID: 25465279     DOI: 10.3109/10715762.2014.991724

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  7 in total

1.  Prohibitin confers cytoprotection against ISO-induced hypertrophy in H9c2 cells via attenuation of oxidative stress and modulation of Akt/Gsk-3β signaling.

Authors:  Debabrata Chowdhury; Dinesh Kumar; Utpal Bhadra; Tangutur Anjana Devi; Manika Pal Bhadra
Journal:  Mol Cell Biochem       Date:  2016-11-16       Impact factor: 3.396

2.  Simvastatin reverses cardiomyocyte hypertrophy via the upregulation of phosphatase and tensin homolog expression.

Authors:  Yong-Qing Chen; Lian-You Zhao; Wei-Ze Zhang; Tao Li
Journal:  Exp Ther Med       Date:  2015-06-05       Impact factor: 2.447

3.  Prohibitin inhibits high glucose-induced apoptosis via maintaining mitochondrial function in human retinal capillary endothelial cells.

Authors:  Li Zhang; Ying He
Journal:  Exp Ther Med       Date:  2022-05-05       Impact factor: 2.751

Review 4.  Multifaceted role of prohibitin in cell survival and apoptosis.

Authors:  Ya-Ting Peng; Ping Chen; Ruo-Yun Ouyang; Lei Song
Journal:  Apoptosis       Date:  2015-09       Impact factor: 4.677

5.  Prohibitin overexpression improves myocardial function in diabetic cardiomyopathy.

Authors:  Wen-qian Dong; Min Chao; Qing-hua Lu; Wei-li Chai; Wei Zhang; Xue-ying Chen; Er-shun Liang; Ling-bo Wang; Hong-liang Tian; Yu-guo Chen; Ming-xiang Zhang
Journal:  Oncotarget       Date:  2016-01-05

6.  A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation.

Authors:  Cristina Moncunill-Massaguer; José Saura-Esteller; Alba Pérez-Perarnau; Claudia Mariela Palmeri; Sonia Núñez-Vázquez; Ana M Cosialls; Diana M González-Gironès; Helena Pomares; Anne Korwitz; Sara Preciado; Fernando Albericio; Rodolfo Lavilla; Gabriel Pons; Thomas Langer; Daniel Iglesias-Serret; Joan Gil
Journal:  Oncotarget       Date:  2015-12-08

Review 7.  Prohibitins: A Critical Role in Mitochondrial Functions and Implication in Diseases.

Authors:  Anna Signorile; Giuseppe Sgaramella; Francesco Bellomo; Domenico De Rasmo
Journal:  Cells       Date:  2019-01-18       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.